Literature DB >> 17355886

Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro.

Esther D Quakkelaar1, Evelien M Bunnik, Floris P J van Alphen, Brigitte D M Boeser-Nunnink, Ad C van Nuenen, Hanneke Schuitemaker.   

Abstract

Although the majority of primary HIV-1 variants can be neutralized by broadly neutralizing antibodies such as b12, 2G12, 2F5 and 4E10, resistance to these antibodies has been reported as well. The ability of the broadly neutralizing antibodies to inhibit a variety of viruses suggests that their epitopes are conserved and escape from these antibodies may thus come at a cost to viral fitness. Here we demonstrate that resistance to broadly neutralizing antibodies was in general not associated with a reduced replicative capacity of the virus in vitro. This indicates that loss of replicative capacity due to escape from broadly neutralizing antibodies may be limited.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17355886     DOI: 10.1016/j.virol.2007.02.011

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

1.  The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter.

Authors:  Rebecca M Lynch; Rong Rong; Saikat Boliar; Anurag Sethi; Bing Li; Joseph Mulenga; Susan Allen; James E Robinson; S Gnanakaran; Cynthia A Derdeyn
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

2.  Selection of a rare neutralization-resistant variant following passive transfer of convalescent immune plasma in equine infectious anemia virus-challenged SCID horses.

Authors:  Sandra D Taylor; Steven R Leib; Susan Carpenter; Robert H Mealey
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

3.  Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies.

Authors:  Marit J van Gils; Evelien M Bunnik; Brigitte D Boeser-Nunnink; Judith A Burger; Marijke Terlouw-Klein; Naomi Verwer; Hanneke Schuitemaker
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

4.  The human immunodeficiency virus type 1 envelope confers higher rates of replicative fitness to perinatally transmitted viruses than to nontransmitted viruses.

Authors:  Xiaohong Kong; John T West; Hong Zhang; Danielle M Shea; Tendai J M'soka; Charles Wood
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

5.  Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1.

Authors:  Catherine A Blish; Zahra Jalalian-Lechak; Stephanie Rainwater; Minh-An Nguyen; Ozge C Dogan; Julie Overbaugh
Journal:  J Virol       Date:  2009-05-27       Impact factor: 5.103

6.  Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.

Authors:  Esther D Quakkelaar; Floris P J van Alphen; Brigitte D M Boeser-Nunnink; Ad C van Nuenen; Ralph Pantophlet; Hanneke Schuitemaker
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

7.  High-Resolution Sequencing of Viral Populations during Early Simian Immunodeficiency Virus Infection Reveals Evolutionary Strategies for Rapid Escape from Emerging Env-Specific Antibody Responses.

Authors:  Sergio Ita; Alison K Hill; Evan C Lam; Fay J Dufort; Xiao Yang; Ruchi Newman; Sivan Leviyang; Ismael B Fofana; Welkin E Johnson
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

8.  Increased sensitivity to broadly neutralizing antibodies of end-stage disease R5 HIV-1 correlates with evolution in Env glycosylation and charge.

Authors:  Marie Borggren; Johanna Repits; Jasminka Sterjovski; Hannes Uchtenhagen; Melissa J Churchill; Anders Karlsson; Jan Albert; Adnane Achour; Paul R Gorry; Eva Maria Fenyö; Marianne Jansson
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

Review 9.  Peptide Vaccine: Progress and Challenges.

Authors:  Weidang Li; Medha D Joshi; Smita Singhania; Kyle H Ramsey; Ashlesh K Murthy
Journal:  Vaccines (Basel)       Date:  2014-07-02

10.  HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds.

Authors:  Tom L G M van den Kerkhof; Steven W de Taeye; Brigitte D Boeser-Nunnink; Dennis R Burton; Neeltje A Kootstra; Hanneke Schuitemaker; Rogier W Sanders; Marit J van Gils
Journal:  Retrovirology       Date:  2016-07-07       Impact factor: 4.602

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.